NASEEMA KAPADIA, GULNAZ KHALID, TASNEEM BURHANY.

ABSTRACT

Objective: To evaluate the clinical response of 13 cis retinoic acid in nodulocystic acne.

Materials and Methods: Eighteen patients with severe nodulocystic acne were selected from the out patient derma clinics of Abbassi Shaheed Hospital and Aga Khan University Hospital. They were treated with either 20mg/day and 40mg/day of 13 cis retinoic acid for 24 weeks.

Results: A marked dose related decrease in acne lesions was noted within four weeks of the onset of therapy in all patients. Clinical improvement was measured on an acceptable global assessment scale. 95% clearances were noted in 16 weeks, the drug was continued till 24 weeks as a maintenance therapy, to prevent relapses. Chelitis, pruritus and desquamation of skin were the most common clinical side effects. No laboratory abnormalities were noted at the start or end of therapy.

Conclusion: 13 cis retinoic acid is a miracle drug in moderate to severe nodulocystic acne. Excellent compliance despite side effects and cost, proves its efficacy and tolerability.

For Full text contact to:
Prof. Dr. Farah Mansuri
editor@annals-ashkmdc.org

Associate Professor Dermatology, Karachi Medical & Dental College, Consultant Dermatologist, The Aga Khan University Hospital, Karachi *
Assistant Professor Pathology KMDC and Abbasi Shaheed Hospital, Karachi *
Medical officer, Executive Clinic, AKUH *